| Filed On | Filing |
|---|---|
| 16 Oct 2025 |
8-K/A: Financial Statements and Exhibits
On July 31, 2025, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") completed the acquisition ("Acquisition") of Sage Therapeutics, Inc. ("Sage"). The following unaudited pro forma condensed combined statements of operations (... |
| 10 Aug 2023 |
8-K/A: Results of Operations and Financial Condition
–$31.0 million and $56.8 million of net product sales in the second quarter and first six months of 2023, respectively |
| 10 Feb 2022 | 8-K/A: Financial Statements and Exhibits |
| 24 Aug 2020 | 8-K/A: Financial Statements and Exhibits |
| 09 Nov 2017 | 8-K/A: Submission of Matters to a Vote of Security Holders |
| 11 Mar 2015 | 8-K/A: Results of Operations and Financial Condition |
Loading...
